174 related articles for article (PubMed ID: 15975641)
1. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Miller DS; Blessing JA; Schilder J; Munkarah A; Lee YC
Gynecol Oncol; 2005 Aug; 98(2):217-21. PubMed ID: 15975641
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Curtin JP; Blessing JA; Soper JT; DeGeest K
Gynecol Oncol; 2001 Nov; 83(2):268-70. PubMed ID: 11606082
[TBL] [Abstract][Full Text] [Related]
3. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
[TBL] [Abstract][Full Text] [Related]
4. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
Wadler S; Levy DE; Lincoln ST; Soori GS; Schink JC; Goldberg G
J Clin Oncol; 2003 Jun; 21(11):2110-4. PubMed ID: 12775736
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
6. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Muderspach LI; Blessing JA; Levenback C; Moore JL
Gynecol Oncol; 2001 May; 81(2):213-5. PubMed ID: 11354055
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; McMeekin DS
Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
[TBL] [Abstract][Full Text] [Related]
8. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
9. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Bookman MA; Blessing JA; Hanjani P; Herzog TJ; Andersen WA
Gynecol Oncol; 2000 Jun; 77(3):446-9. PubMed ID: 10831357
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; Waggoner SE
Gynecol Oncol; 2002 Dec; 87(3):247-51. PubMed ID: 12468321
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
Temkin SM; Yamada SD; Fleming GF
Gynecol Oncol; 2010 Jun; 117(3):473-6. PubMed ID: 20347480
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
Fowler JM; Blessing JA; Burger RA; Malfetano JH
Gynecol Oncol; 2002 May; 85(2):311-4. PubMed ID: 11972393
[TBL] [Abstract][Full Text] [Related]
17. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.
Möbus V; Pfaff PN; Volm T; Kreienberg R; Kaubitzsch S
Anticancer Res; 2001; 21(5):3551-6. PubMed ID: 11848522
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
Miller DS; Blessing JA; Kilgore LC; Mannel R; Van Le L
Am J Clin Oncol; 2000 Aug; 23(4):355-7. PubMed ID: 10955863
[TBL] [Abstract][Full Text] [Related]
19. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
